Biocept (BIOC) Stock Pops On New Patent Award

Biocept BIOC Stock News

Biocept Inc (NASDAQ: BIOC) is flying in the market this morning, trading on gains of more than 17%. The gains come after the company announced that it has been awarded a new patent. Here’s the scoop:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

BIOC Stock Pops After Being Awarded A New Patent

Biocept issued a press release this morning announcing that it has been awarded a new patent. The company, focused on molecular offerings that provide physicians with clinically actionable information to improve cancer outcomes, has been awarded Patent No. 10,527,611.

The patent that was awarded is titled DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS and was awarded by the United States Patent and Trademark Office.

In the release, BIOC said that the patnet covers devices for the detection of cells of interest, including circulating tumor cells, that are shed into the bloodstream by solid tumors where an antibody, or mixture of antibodies, and any solid surface are used for cell capture, detection, and analysis.

Importantly, the patent includes any biological sample type of interest and includes the use of single antibodies or a cocktail of antibodies.

In a statement, Lyle Arnold, Ph.D., CSO at BIOC, had the following to offer:

The granting of this patent broadly expands Biocept’s intellectual property estate for capturing and detecting cells of interest using antibodies, which combines nicely with our patented microchannel and cell staining platforms. This allowed patent also interfaces very well with our other patented technologies that include a blood collect tube, and ctDNA analysis platforms for aiding patient treatment decisions.

The above statement was follwed up by Michael Nall, President and CEO at BIOC. Here’s what he had to say:

We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter. We are very proud of our innovations in the industry and look forward to sharing future applications for this patented technology to capture cellular targets in biological fluids, even when found in very small quantities.

Investors Are Excited For Very Good Reasons

With this new patent in mind, there are plenty of reasons to be excited. First and foremost, when combining this patent with the company’s patented microchannel and cell staining platform technologies, Biocept has officially patented the capability to enable the capture of any cell of interest.

Importantly, cells of interest include very rare cells that could be present in blood and any other biological sample type.

For those of you who have followed my work for some time, you know that BIOC is a stock that I believe will become a major player in the long run. The company’s liquid biopsy technologies make it possible to detect cancer faster without putting the patient under any undue stress or pain. With this new patent, in my view, the company has essentially built an economic moat around itself, setting the stage for strong, competitionless growth ahead.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.